Promega, G9302, ADCC Reporter Bioassay, F Variant

MOA-Based Bioassay to Measure FcγRIIIa (F158) Function
No cell culture required
Quantitate impact of F158 polymorphism on Fc effector function
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
ADCC Bioassay Effector Cells, F Variant G979A 1 × 1 vial
Low IgG Serum G711A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
ADCC Bioassay Effector Cells, F Variant G979A 5 × 1 vial
Low IgG Serum G711A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
ADCC Bioassay Effector Cells, F Variant (CPM) G930A 2 × 1ml
Fc receptor-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) by which antibodies target disease cells for elimination.
The ADCC Reporter Bioassays, F Variant, use NFAT-mediated luciferase activity in effector cells as indicator of ADCC MOA, providing an alternative to traditional primary cell-based assays for measuring the effect of biologics on ADCC activity.
They are accurate, precise and stability-indicating and prequalified according to ICH guidelines, making them suitable for all stages of biologic research and development.